Literature DB >> 32417203

Priorities and Preferences of Patients With Head and Neck Cancer for Discussing and Receiving Information About Sexuality and Perception of Self-Report Measures.

Bethany A Rhoten1, Amanda J Davis2, Breanna N Baraff2, Kelly H Holler2, Mary S Dietrich2.   

Abstract

BACKGROUND: Head and neck cancer and its treatment can cause impairment in survivors' sexuality. Previous studies show a need for education and psychological support. AIM: To examine patients' priorities and preferences for discussing and receiving information about sexuality and to examine patient perceptions of existing self-report measures used in research.
METHODS: This descriptive, cross-sectional, Web-based study recruited adults with a current or previous diagnosis of head and neck cancer. Participants answered questions about their priority and preference for receiving information about sexuality and reviewed 4 self-report measures commonly used in the research of this population.
RESULTS: More than 80% (n = 61) of participants reported that it was important to receive information about sexual issues. Participants chose "at the time of diagnosis" as the most frequent answer for preferred time to receive this information. Half of the participants (n = 35) indicated that they prefer discussing sexual issues with a health-care provider. The most frequent answer for the method of receiving information was through discussions. Participants endorsed 4 themes not addressed by self-report surveys: (i) elicitation of important information, (ii) symptom burden issues, (iii) psychological issues, and (iv) physical barriers. CLINICAL IMPLICATIONS: Providers, regardless of specialty, must attempt or facilitate discussions around these issues at various times within the treatment and recovery phases. STRENGTHS & LIMITATIONS: Although limited by sample representation and cross-sectional design, this study addresses an important patient-centered issue that is a critical aspect of quality of life.
CONCLUSIONS: Patients prefer to discuss sexual issues in person with their health-care providers at the time of diagnosis. Participants reacted positively to the self-report measures, but they felt that important issues faced by patients with head and neck cancer were not fully addressed. Rhoten BA, Davis AJ, Baraff BN, et al. Priorities and Preferences of Patients With Head and Neck Cancer for Discussing and Receiving Information About Sexuality and Perception of Self-Report Measures. J Sex Med 2020;17:1529-1537.
Copyright © 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Head and Neck Neoplasms; Patient Preference; Patient-Centered Care; Self-Report; Sexual Health; Sexuality; Surveys and Questionnaires

Mesh:

Year:  2020        PMID: 32417203      PMCID: PMC7664992          DOI: 10.1016/j.jsxm.2020.04.001

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  27 in total

1.  Why don't we mention "impact on intimacy" when we ask patients to give consent for treatment of oral cancer?

Authors:  R Ratansi; J Hoole; D A Mitchell; A Kanatas
Journal:  Br J Oral Maxillofac Surg       Date:  2017-06-17       Impact factor: 1.651

2.  Longitudinal evaluation of quality of life in Laryngeal Cancer patients treated with surgery.

Authors:  Anh The Bui; Keven Seung Yong Ji; Canh Tuan Pham; Ky Minh Le; Thang Xuan Tong; Walter Tsong Lee
Journal:  Int J Surg       Date:  2018-09-24       Impact factor: 6.071

3.  The course of sexual interest and enjoyment in head and neck cancer patients treated with primary (chemo)radiotherapy.

Authors:  H C Melissant; F Jansen; L E R Schutte; B I Lissenberg-Witte; J Buter; C R Leemans; M A Sprangers; M R Vergeer; E T M Laan; I M Verdonck-de Leeuw
Journal:  Oral Oncol       Date:  2018-06-22       Impact factor: 5.337

4.  Unmet supportive care needs in patients treated with total laryngectomy and its associated factors.

Authors:  Femke Jansen; Simone Elisabeth Jacoba Eerenstein; Birgit Ilja Lissenberg-Witte; Cornelia Foekje van Uden-Kraan; Charles René Leemans; Irma Maria Verdonck-de Leeuw
Journal:  Head Neck       Date:  2018-11-21       Impact factor: 3.147

5.  The REDCap consortium: Building an international community of software platform partners.

Authors:  Paul A Harris; Robert Taylor; Brenda L Minor; Veida Elliott; Michelle Fernandez; Lindsay O'Neal; Laura McLeod; Giovanni Delacqua; Francesco Delacqua; Jacqueline Kirby; Stephany N Duda
Journal:  J Biomed Inform       Date:  2019-05-09       Impact factor: 6.317

6.  Sexual health communication between cancer survivors and providers: how frequently does it occur and which providers are preferred?

Authors:  Nora J Sporn; Kelly B Smith; William F Pirl; Inga T Lennes; Kelly A Hyland; Elyse R Park
Journal:  Psychooncology       Date:  2014-12-22       Impact factor: 3.894

7.  Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35.

Authors:  K Bjordal; E Hammerlid; M Ahlner-Elmqvist; A de Graeff; M Boysen; J F Evensen; A Biörklund; J R de Leeuw; P M Fayers; M Jannert; T Westin; S Kaasa
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

Review 8.  Epidemiology of HPV-associated oropharyngeal cancer.

Authors:  Kristen B Pytynia; Kristina R Dahlstrom; Erich M Sturgis
Journal:  Oral Oncol       Date:  2014-01-22       Impact factor: 5.337

9.  Patient Discussion About Sexual Health With Health Care Providers After Cancer-A National Survey.

Authors:  Ali Ben Charif; Anne-Déborah Bouhnik; Blandine Courbiere; Dominique Rey; Marie Préau; Marc-Karim Bendiane; Patrick Peretti-Watel; Julien Mancini
Journal:  J Sex Med       Date:  2016-09-26       Impact factor: 3.802

Review 10.  Impact of human papillomavirus on oropharyngeal cancer biology and response to therapy: implications for treatment.

Authors:  Juliana Bonilla-Velez; Edmund A Mroz; Rebecca J Hammon; James W Rocco
Journal:  Otolaryngol Clin North Am       Date:  2013-06-27       Impact factor: 3.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.